Last updated: 11/07/2018 18:52:25
A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg twice daily Diskus Fluticasone Propinate 250 mcg twice daily Diskus In Adolescents and Adults With Moderate to Persistent Asthma
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg twice daily Diskus Fluticasone Propinate 250 mcg twice daily Diskus In Adolescents and Adults With Moderate to Persistent Asthma
Trial description: A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg twice daily Diskus Fluticasone Propinate 250 mcg twice daily Diskus In Adolescents and Adults With Moderate to Persistent Asthma
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: Effect of fluticasone propionate (fp)/salmeterol 100/50mcg or fp 250mcg on small airway function. Dorinsky, P., Yancey, S., Rickard, K., and Nelson, H. 13th Annual Congress of the European Respiratory Society 9/27/2003 Vienna; Austria
Abstract: Long-term effectiveness of the fluticasone propionate/salmeterol (fsc) 100150 mcg combination product as an inhaled corticosteroid sparing agent. P. Dorinsky S. Yancey D. Reilly L. Edwards K. Rickard 60th Anniversary Meeting of the American Academy of Allergy, Asthma and Immunology 3/7/2003 Denver CO
Abstract: The combination of salmeterol and low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. Matz, J MD, Kalberg, C MD, Emmett, A MD, Yancey, S MD, Dorinsky, P MD, and Rickard, K MD. American Academy of Allergy, Asthma and Immunology 56th Annual Meeting 3/3/2000 San Diego CA
Abstract: The fluticasone propionate/salmeterol (fsc) combination product 100/50 mcg bid is steroid sparing in patients who require fp250 mcg bid for asthma stability. Sahn, S A, Yancey, S, Reilly, D, Edwards, L, Rickard, K, and Dorinsky, P. 68th Annual International Scientific Assembly and the Clinical World Congress on Diseases of the Chest 11/2/2002 San Diego CA
Clinical: Busse W, Koenig SM, Oppenheimer J, et al. Steroid-sparing effects of fluticasone propionate 100mcg and salmeterol 50mcg BID administered in a single product in patients previously controlled with FP 250mcg BID. J Allergy Clin Immunol 2003; 111:57-65.
Dorinsky P, Yancey S, Reilly D, Edwards L, Rickard K, Nelson H.Effect of fluticasone propionate (FP)/salmeterol 100/50mcg or FP 250mcg on small airway function. Eur Respir J 2003; 22 (suppl 22): 260s, P1707
Dorinsky P, Yancey S, Reilly D, Edwards L, Rickard K. Long-term Effectiveness of the Fluticasone Propionate/Salmeterol (FSC) 100/50mcg Combination Product as an Inhaled Corticosteroid Sparing. J Allergy Clin Immunol 2003; 11 (2): S125
Medical condition
Asthma
Product
fluticasone propionate/salmeterol
Collaborators
Not applicable
Study date(s)
July 2000 to January 2002
Type
Not applicable
Phase
4
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2002-11-01
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website